Chromatin modulators are emerging as attractive drug targets, given their widespread implication in human cancers and susceptibility to pharmacological inhibition. Here we establish the histone methyltransferase G9a/ EHMT2 as a selective regulator of fast proliferating myeloid progenitors with no discernible function in hematopoietic stem cells (HSCs). In mouse models of acute myeloid leukemia (AML), loss of G9a significantly delays disease progression and reduces leukemia stem cell (LSC) frequency. We connect this function of G9a to its methyltransferase activity and its interaction with the leukemogenic transcription factor HoxA9 and provide evidence that primary human AML cells are sensitive to G9A inhibition. Our results highlight a clinical potential of G9A inhibition as a means to counteract the proliferation and self-renewal of AML cells by attenuating HoxA9-dependent transcription.
The involvement of epigenetic regulators like MLL (Tkachuk et al. 1992) , EZH2 (Morin et al. 2010) , DNMT3A (Ley et al. 2010) , and TET2 (Delhommeau et al. 2009 ) in the pathology of human leukemias has stimulated a great deal of interest in identifying chromatin-modifying enzymes that can be targeted therapeutically (Arrowsmith et al. 2012; Dawson and Kouzarides 2012) . For example, a catalytic inhibitor of DOT1L interferes with the oncogenic activity of MLL fusions often found in pediatric leukemias (Daigle et al. 2011) . Furthermore, LSD1/KDM1A inhibition suppresses acute myeloid leukemia (AML) stem cell activity (Harris et al. 2012; Schenk et al. 2012) , and disruption of the chromatin binding of Brd4 by a BET bromodomain inhibitor blocks c-Myc expression and the proliferation of leukemic cells (Delmore et al. 2011; Zuber et al. 2011) . To date, several inhibitors of histone methyltransferases and demethylases have been reported, including those that target G9a and GLP with high specificity (Kubicek et al. 2007; Vedadi et al. 2011; Yuan et al. 2012 ). G9a/GLP uniquely catalyze mono-and dimethylation of histone 3 on Lys9 (H3K9me1/2) (Tachibana et al. 2002 (Tachibana et al. , 2005 , a highly abundant chromatin mark in mammalian cells. G9a/GLP take part in a number of corepressor complexes, and H3K9me2 is enriched at inactive loci (Barski et al. 2007; Dong et al. 2008) and CpG islands (Lienert et al. 2011 ). In addition, G9a can activate transcription at least in part by acting as a cofactor for the Mediator complex (Chaturvedi et al. 2012) . Interestingly, H3K9me2-enriched domains are mostly devoid of H3K27me3 mediated by Ezh1/2 (Lienert et al. 2011) , suggesting that G9a/GLP-dependent pathways govern the expression of genes involved in cell differentiation in addition to those that are subject to PRC2-dependent repression. This has been demonstrated in certain contexts, as G9a mediates T-helper cell diversification (Lehnertz et al. 2010 ) and embryonic stem cell (ESC) differentiation (Feldman et al. 2006) . Furthermore, G9A/GLP inhibition delays the differentiation of human hematopoietic stem cells (HSCs) ex vivo , suggesting additional roles in early hematopoiesis. Despite recent ad-Ó 2014 Lehnertz et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at http:// creativecommons.org/licenses/by-nc/3.0/. vances in delineating biological roles of G9a/GLP, a detailed characterization of these enzymes during hematopoiesis has not been reported.
Results

Selective requirement for G9a in hematopoietic progenitor cells
To confirm the expression of G9a in the hematopoietic system, we performed quantitative RT-PCR (qRT-PCR) analyses from FACS-purified hematopoietic subpopulations and detected high expression of G9a in hematopoietic stem and progenitor cells (HSPCs), at levels comparable with mouse ESCs, and the lowest expression in mature myeloid and lymphoid cells (Supplemental Fig. S1 ). We then investigated the biological importance of G9a in the hematopoietic system using G9a fl mice ( Fig. 1A ; Lehnertz et al. 2010 ) crossed with Vav-Cre transgenic mice to obtain G9a and G9a
, hereafter]. As expected (Stadtfeld and Graf 2005; Gan et al. 2010 ), Vav-Cre-mediated excision in G9a À/À (Vav) mice harboring a ROSA26-YFP (R26-YFP) Cre reporter was specific to hematopoietic cells and fully penetrant . Consistent with previous reports (Tachibana et al. 2002 (Tachibana et al. , 2005 , deletion of G9a resulted in a characteristic reduction in GLP and H3K9me2 levels in bone marrow-derived macrophages (BMMs) (Fig. 1B) . G9a À/À (Vav) mice also exhibited efficient deletion of G9a in lymphoid cells, were born at normal frequency, and did not display any overt hematological abnormalities (Lehnertz et al. 2010) .
We first investigated the function of G9a-deficient progenitor cells and evaluated the ability of bone marrow cells from G9a +/À (Vav) and G9a À/À (Vav) mice to form colonies in cytokine-containing methylcellulose medium. While no difference in colony-forming unit (CFU) numbers (Fig. 1C) and phenotypes ( Fig. 1D) was observed, the total cell output of G9a-deficient progenitors was drastically decreased (Fig. 1E) . This was the result of a reduction in the size of individual colonies, most of which contained <500 cells (Fig. 1F,I ).
To assess the activity of G9a-deficient HSCs, we generated mixed bone marrow chimeras with R26-YFP
). Interestingly, we observed only a modest, nonsignificant difference in the relative output of G9a
and G9a À/À (Vav) cells in the examined lineages 8 wk after transplantation. (Fig. 1I) . However, this trend was no longer detectable 18 wk after transplantation (Fig. 1J) , suggesting that G9a is not essential for the function of long-term repopulating HSCs (LT-HSCs).
Loss of G9a impairs AML progression and leukemia stem cell (LSC) self-renewal in vivo
To investigate G9a function in AML cells, which partially resemble myeloid progenitors (Krivtsov et al. 2006) , we generated leukemias from knockout and heterozygous HSPCs by retroviral expression of HoxA9 and Meis1 (A9M) (Supplemental Fig. S3 ; Kroon et al. 1998) , two genes frequently overexpressed in human AML (Lawrence et al. 1999) . Importantly, G9a and GLP were expressed in G9a
; A9M cells, and G9a expression was entirely ablated in G9a
; A9M cells ( Fig. 2A) (Fig.  2B ). In addition, clonal analysis of HoxA9/Meis1 proviral DNA in the G9a À/À (Vav) cohort revealed identical integration patterns in more than one recipient, indicative of a reduced repertoire of self-renewing LSC clones (Fig.  2C ). To confirm this notion, we performed an in vivo limiting dilution assay (LDA) using bone marrow cells harvested from end-stage leukemic mice (Fig. 2D) and found that the frequency of LSCs among G9a À/À (Vav) ; A9M cells was reduced ;20-fold (Fig. 2E) .
We also generated A9M leukemias from G9a fl/fl ; Mx-Cre + mice, allowing the inducible deletion of G9a in vivo following pIpC treatment (Supplemental Fig. S4a ). pIpC treatment per se had no effect in primary recipients of G9a fl/+ (Mx) ; A9M cells (Supplemental Fig. S4b ). In contrast, deletion of G9a in secondary leukemia recipients of G9a fl/fl (Mx) ; A9M cells led to a dramatic reduction in circulating leukemic cells after 12 d (Fig. 2E,F) and a significantly increased median survival of pIpC-treated mice (44 d vs. 23.5 d) (Fig. 2G) . Importantly, G9a deficiency similarly delayed disease progression of MN1-induced or MLL-AF9-induced experimental AML (Supplemental Fig. S5a,b) , suggesting that this enzyme acts through a general mechanism and plays a role in multiple leukemias.
G9a regulates expansion and differentiation of AML cells through its methyltransferase activity
We additionally assessed the effects of G9a deletion on AML cells in vitro. G9a
; A9M cells displayed a substantial growth impairment, with a >2.5-fold increase in population doubling time (;37 h vs. 14 h), resulting in a vastly reduced cumulative cell output compared with controls ( Fig. 3A,B ). This correlated with significantly more cells in G 1 /G 0 but no increase in apoptosis ( Fig. 3C ; Supplemental Fig. S6 ). Importantly, loss of p53 did not rescue this growth deficiency, indicating that a p53-dependent senescence pathway was not responsible for this phenotype (Fig. 3A) . To determine whether the catalytic activity of G9a was required for efficient AML cell proliferation, we reintroduced wild-type or a methyltransferase-inactive mutant of G9a (H1166K) into G9a À/À (Vav) ; A9M cells using an MSCV-ires-GFP (MIG) retroviral vector (Fig. 3D) . Infection with MIG-G9a
WT conferred a competitive growth advantage to transduced (GFP + ) over untransduced (GFP À ) cells as indicated by their rapid takeover of the culture. In contrast, control-infected (empty MIG) and MIG G9a H1166K -infected cells displayed no growth advantage or even a slight disadvantage, respectively ( Fig. 3E,F) . Likewise, reintroduction of G9a ) from a diseased primary recipient were transplanted into irradiated secondary recipients. Control mice (G9a fl/fl (Mx) ) were left untreated, whereas test mice (G9a À/À (Mx) ) received four injections of pIpC to stimulate Cre expression and abrogate G9a expression. The abundance of peripheral AML cells was assessed by CD45.2 staining in recipients 12 d after pIpC treatment. G9a inactivation in the G9a À/À (Mx) cohort resulted in a significant decrease of peripheral AML cells. Representative FACS plot is shown in E; statistical summary is shown in F (n = 6 for untreated; n = 7 for treated; P < 0.0001 using unpaired t-test). (H) A significant delay in AML progression in the G9a-depleted cohort (G9a À/À (Mx) ) was observed (n = 6 for untreated; n = 7 for treated; P < 0.0001 using log rank test). A9M cells of the indicated genotypes were generated as in Figure 2A . The resulting leukemia cell lines were maintained in culture to assess their growth kinetics. G9a-deficient cultures were characterized by severely reduced proliferation. Compound deletion of p53 did not rescue this growth defect. Each individual experiment originating from distinct donor bone marrow is represented by a separate curve. Cold
their ability to initiate AML in transplanted recipient mice (Fig. 3G) . Notably, ectopic expression of G9a WT in G9a
; A9M cells significantly accelerated AML progression, demonstrating that elevated levels of G9a increase AML aggressiveness in vivo (Fig. 3G) . These results suggested that catalytic inhibition of G9a should mimic the phenotype observed in G9a À/À (Vav) cells. Indeed, treatment with the G9a/GLP inhibitor UNC0638 (Vedadi et al. 2011 ) inhibited the growth of G9a
; A9M cells in vitro (Fig. 3H) . Furthermore, whereas G9a
; A9M cells exhibited a characteristic blast-like morphology with a high nucleus to cytosol ratio and the absence of granular cytosolic structures, both G9a-deficient and UNC0638-treated AML cells displayed a significant degree of myeloid differentiation (Fig. 3I) . Taken together, these results indicate that the methyltransferase activity of G9a is critical to maintain high proliferation rates and the incomplete differentiation characteristic of AML cells.
G9a regulates HoxA9-dependent gene expression
G9a was previously linked to the transforming activity of Evi-1/Prdm3 (Goyama et al. 2009 ), a Zn finger containing H3K9-specific monomethyltransferase (Pinheiro et al. 2012) whose expression is independently correlated with poor prognosis in AML. Since Evi-1 is critical for the function of HSCs as well as normal and transformed progenitors (Goyama et al. 2008 ), whereas G9a is not required for HSC function, we thus reasoned that G9a likely plays important roles independently of its connection with Evi-1. A number of considerations led us to hypothesize that G9a may exert its role in AML cells by facilitating HoxA9-dependent gene expression. First, although HoxA9 plays important roles in HSPCs, HoxA9-deficient mice are viable and, compared with Evi-1 mutants, display a relatively mild hematopoietic phenotype (Lawrence et al. 1997 (Lawrence et al. , 2005 ) that in some respects resembles that of G9a À/À (Vav) mice. Second, HoxA9 elicits its oncogenic activity in AML cells by enforcing self-renewal and impairing myeloid differentiation, both of which were affected in G9a À/À (Vav) AML cells. Third, overexpression of wild-type but not catalytically dead G9a accelerates the pathogenesis of HoxA9/ Meis1-driven AML, suggesting that endogenous levels of G9a are limiting in this model and that it may play a direct role in HoxA9-regulated transcription mediated through its methyltransferase activity. To assess this hypothesis, we first asked whether a physical interaction between HoxA9 and G9a takes place. To this end, we performed coimmunoprecipitation studies using Flag-and HA-tagged versions of G9a and HoxA9, respectively. Indeed, we could detect a robust interaction between G9a and HoxA9 following immunoprecipitation with anti-Flag or anti-HA antibodies (Fig. 4A) , suggesting that G9a is recruited to sites of HoxA9-dependent transcription. Next, we investigated whether the methyltransferase activity of G9a is required to facilitate HoxA9-dependent gene expression in mouse AML cells. To this end, we performed microarray analysis to assess changes in gene expression in HoxA9-and Meis1-expressing leukemic cells treated with UNC0638 for 5 d in comparison with mock-treated controls (Supplemental Fig. S7a) . We then compared this data set to that of a study that used an estrogen receptorcoupled version of HoxA9 (HoxA9-ER) together with Meis1 to generate mouse AML cells. These cells were initially cultured in the presence of 4-hydroxy-tamoxifen (4OHT) to allow HoxA9 function and then transferred to medium lacking 4OHT for 5 d prior to measuring HoxA9-dependent gene expression (Supplemental Fig.  S7b ; Huang et al. 2012) . Strikingly, gene set enrichment analysis (GSEA) revealed a highly significant overlap between genes that responded to UNC0638 treatment in HoxA9/Meis1 and those that responded to 4OHT withdrawal in HoxA9-ER/Meis1 cells (Fig. 4B,C) . This was consistent with a decrease in the expression of LSCassociated genes and an increase in granulocyte-specific genes in response to UNC0638 or 4OHT withdrawal in the respective data sets (Supplemental Fig. S7c,d ), confirming the loss of a self-renewal signature and increased myeloid differentiation in both of these conditions. To assess whether the overlap between G9a-dependent and HoxA9-dependent gene expression changes was due to a direct effect on HoxA9 target genes or a secondary effect due to increased differentiation in both conditions, we restricted GSEA only to genes that had been shown to be bound by HoxA9 in their vicinity and whose expression either decreased or increased by >1.5-fold upon 4OHT withdrawal in HoxA9-ER/Meis1-expressing cells . Importantly, we found that HoxA9-occupied genes respond to UNC0638 treatment and HoxA9 withdrawal (by removal of 4OHT) predominantly in the same way and that this overlap is highly significant in both directions (Fig.  4C,D) . Taken together, these data demonstrate that G9a partakes in the regulation of HoxA9-dependent gene expression in AML cells, suggesting that the observed phenotypes in UNC0638-treated AML cells are at least partially caused by the attenuation of a HoxA9-dependent gene signature.
Sensitivity to G9A/GLP inhibition is conserved in human AML specimens
To assess whether G9A inhibition also affects the growth of human AML cells, we cultured primary human AML cells (normal karyotype, NPM1 wt /FLT3 wt ) in the presence or absence of UNC0638 for up to 7 d. Reminiscent of our observation with murine A9M cells, UNC0638 inhibited human AML cell proliferation (Fig. 5A-C) and triggered differentiation. This was evident morphologically (Fig. 5D) and from an increase in the mast cell surface marker FceR1a (Fig. 5E ). In addition, UNC0638 treatment of human mobilized CD34 + HSPCs plated in methylcellulose led to a characteristic reduction in colony size identical to that observed in murine G9a À/À (Vav) progenitor cultures (Supplemental Fig. S8 ). To perform a more representative assessment of G9A's requirement in human AML proliferation, we tested the response of 15 additional and genetically diverse primary AML specimens toward UNC0646, an improved version of the UNC0638 G9A/ GLP inhibitor ). We detected growthsuppressive activity of UNC0646 in all tested samples, albeit to varying degrees, with IC 50 values ranging from 0.58 mM to 3.73 mM ( Fig. 5F; Supplemental Fig. S9 ). Together, these results indicate that our findings in murine AML models can be extended to humans, demonstrating that G9A/GLP-dependent methylation is an important determinant of human AML proliferation.
Discussion
Our data demonstrate that G9a/GLP-dependent methylation plays an important role in the efficient repression of terminal differentiation programs in AML and thus for efficient LSC self-renewal and proliferation. Strikingly, LSCs exhibit a selective dependency on G9a compared with normal HSCs. This is consistent with the notion that oncogenic mutations of IDH1/2 (Mardis et al. 2009 ) result in elevated levels of histone marks like H3K9me2 deposited by G9A and GLP via inhibition of corresponding histone demethylases (Lu et al. 2012) . Based on the results presented in this study, it is tempting to speculate that in an AML context, mutant IDH1/2 might specifically modulate target gene expression of HOXA9 and/or other transcription factors such as EVI-1, MYB, or MYC, whose roles in the pathogenesis of AML are at least in part mediated by G9A. While this would predict a more pronounced sensitivity of IDH1/2 mutant AML cells to inhibitors of G9A/ GLP or other methyltransferases, testing of much larger cohorts of genetically characterized human AML specimens is necessary to substantiate this hypothesis. ) immunoprecipitations were subjected to Western analysis using anti-Flag or anti-HA antibodies to visualize G9a (top) and HoxA9 (bottom), respectively. Robust reciprocal interaction between G9a and HoxA9 were detected. (B-E) GSEA plot evaluating changes in gene expression in A9M cells subjected to 1 mM UNC0638 (5 d). In B, genes that are down-regulated $1.5-fold upon HoxA9 inactivation in Huang et al. (2012) correlate with control-treated A9M cells and are predominantly down-regulated upon UNC0638 treatment. Conversely, in C, genes that are up regulated $1.5-fold upon HoxA9 inactivation correlate with genes down-regulated in UNC0638-treated A9M cells. In D and E, GSEA was restricted to direct targets of HoxA9 according to Huang et al. (2012) ; i.e., genes that were both bound by HoxA9 and changed expression 61.5-fold upon HoxA9 inactivation. (NES) Normalized enrichment scores; (FDR Q-values) false discovery rate Q-values, indicating the likelihood of an applied gene set with the indicated NES represents a false-positive finding.
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Cold Spring Harbor Laboratory Press on June 23, 2017 -Published by genesdev.cshlp.org Downloaded from Furthermore, it remains controversial to what extent global H3K9me2 increases during cellular differentiation (Wen et al. 2009; Lienert et al. 2011) , particularly since elevated H3K9me2 and H3K9me3 often correlate with the defective differentiation found in cancerous cells (Lu et al. 2012 ). This controversy is further spurred by the observation that G9A/GLP inhibition can help to maintain the undifferentiated state of human HSCs under ex vivo culture conditions . Our data suggest that the cellular functions of G9a-dependent histone methylation are highly context-dependent and aid the stabilization of transcription programs that are specified by developmental transcription factors such as HoxA9 under normal or malignant circumstances.
From a practical perspective, this study reveals a novel and specific G9a function that is relevant to human biology and disease. By showing that G9a/GLP deletion selectively affects the proliferation of AML cells without detectable adverse effects on HSC function, our data emphasize the pharmacological inhibition of G9A/GLP as a potential targeted therapy.
Materials and methods
Mouse strains
G9a
fl mice (Lehnertz et al. 2010) , Vav-Cre mice (Stadtfeld and Graf 2005) , and R26-YFP mice (Ye et al. 2003) were described earlier, and Mx-Cre mice were obtained from Jackson Laboratory. All strains were maintained on a pure C57/B6 background and used between 6 and 12 wk of age. All procedures were conform with institutional guidelines.
Antibodies for Western analysis
Antibodies used for Western analysis were anti-G9a (clone A8620A, R&D Systems; clone C6H3, Cell Signaling Technology), anti-GLP (clone B0422, R&D Systems), anti-H3H9me2 (ab1220, Abcam), anti-H3 (ab1791, Abcam; clone C6H3, Cell Signaling Technology), anti-Flag (clone M2, Sigma-Aldrich), and anti-HA (clone 12CA5, Roche Applied Science).
Progenitor growth assay
Bone marrow cells were plated at 2 3 10 4 cells per milliliter culture. Methylcellulose medium (M3434, Stem Cell Technologies) was either purchased or generated in-house. CFUs were scored at day 8 after plating.
Competitive bone marrow transplantation experiments
Bone marrow cells from age-and sex-matched mice were mixed 1:1 with YFP À control (G9a
) bone marrow cells. We transplanted 4 3 10 6 cells into lethally irradiated CD45.1 hosts. After 8 and 18 wk, we determined the ratios of YFP-negative (G9a fl/fl ) versus YFP-positive (G9a Bone marrow cell transduction and generation of mouse AML models MSCV HoxA9-ires-Meis PGK-Neo construct was obtained from Mark Kamps (University of California at San Diego). Retroviral infections were essentially done as described (Thorsteinsdottir et al. 2002) . A9M-expressing cells were selected with 1.2 mg/mL G418 and injected into lethally irradiated CD45.1 mice. Recipients were monitored daily and sacrificed at humane AML endpoints according to institutional policy. For in vitro experiments, A9M cells were cultured in mouse AML culture medium (DMEM, 15%FBS, 100 ng/mL rmSCF, 10 ng/mL rmIL-3, 10 ng/mL rhIL-6, L-glutamine, penicillin/streptomycin, 1/100,000 b-mercaptoethanol; cytokines purchased from Stem Cell Technologies) at a plating density of 5 3 10 4 to 2 3 10 5 cells per milliliter.
Secondary AML transplantation experiments
Leukemic bone marrow cells from diseased primary recipient mice were extracted, cryopreserved, and then transplanted into sublethally irradiated secondary recipient mice. Mx-Cre + AML cells were induced with four intraperitoneal injections of pIpC (400 mg; Sigma) at days 3, 5, 7, and 9 after transplantation unless indicated otherwise.
Immunoprecipitation studies
HEK293T cells were subcultured at 60% confluence on 100-mm dishes and transfected with the indicated plasmids using Lipofectamine 2000 transfection reagent (Invitrogen). Fortyeight hours post-transfection, cells were rinsed twice with ice-cold PBS and incubated with RIPA lysis buffer (Santa Cruz Biotechnology). Fifteen microliters of Protein-A/G beads was added to the cell lysates for 30 min at 4°C for preclearing. Fivehundred micrograms of precleared protein was incubated with 4.0 mg of indicated antibodies overnight at 4°C, followed by adding 20 mL of Protein-A/G beads. After a 3-h incubation, the beads were precipitated, washed once with RIPA buffer and twice with PBS, and boiled in 23 loading dye. Samples were separated by 10% SDS-PAGE and transferred to nitrocellulose membrane (Bio-Rad Laboratories). Blots were incubated with the indicated antibodies and visualized using the Odyssey infrared system (LI-COR Biosciences).
Human AML cells
All human AML samples used in these studies were collected by the Quebec Leukemia Cell Bank (BCLQ) with the informed consent and approval of the Leucegene project by the research ethics board of the Maisonneuve-Rosemont Hospital and Université de Montréal. Cryopreserved AML cells were thawed and cultured in serum-free conditions in the presence of SR1 (Alichem, catalog no. 41864) and UM729 (Sauvageau 2013) . UNC0638/ UNC0646 were added to growth medium from a 5 mM DMSO stock solution.
Gene expression and statistical analyses
G9a-dependent gene expression was assessed by comparing DMSO-and UNC0638-treated A9M cells (800 nM, 5 d, three biological replicates per condition). RNA was extracted with Trizol and analyzed on Affimetrix Mouse Gene 1.0 chip (accessible on Gene Expression Omnibus [GEO], GSE53894). HoxA9-dependent gene expression files (Affymetrix Mouse Genome 430 2.0 chip) were downloaded from GEO (GSE21299). CEL files were processed using the ExpressionFileCreator (RMA method) and PreprocessDataSet modules in the Genepattern suite (Broad Institute). GSEA analysis was done using log 2 transformed expression values and the ''difference of classes'' setting with the provided gene sets (Supplemental Table 1 ). All further statistical analyses were done using Flowjo (Treestar) and Graphpad Prism.
